Latest news with #IMI
Globe and Mail
2 days ago
- Business
- Globe and Mail
Report shows that 60% of Canadians see improved perception of women's sport
New data on the explosive growth of women's sport in Canada underscores its rising popularity, but also reveals that its structural supports still lag behind. Jessica Doherty, vice-president of strategy and growth at Torque Strategies, presented findings from a new national survey on Wednesday morning at the espnW Summit Canada at Toronto's Evergreen Brick Works. One of the study's main findings is that 60 per cent of Canadians believe perceptions of women's sport have improved over the past three years. 'It has been on quite a rocket ship and one of the things that feeds into that is just the growing visibility in it,' said Doherty, noting that three professional women's sports properties have been launched in Canada in the past three years. 'I think when people see it more, then they're like, 'Oh, yeah, this is a thing.' It becomes normalized, and therefore, other people think, 'Oh, it's OK for me to be a fan of women's sport.'' Commissioned by Torque Strategies, in partnership with IMI, the report surveyed 2,000 people across a wide demographic spectrum that was representative of Canada's population. It found that 80 per cent of male respondents consider themselves fans of women's sport. According to the report, 41 per cent of Canadians see women's sports as a national investment. The surge in popularity across all genders was, in large part, thanks to the founding of the Professional Women's Hockey League, soccer's Northern Super League, and the announcement that the Women's National Basketball Association will expand into Toronto for the 2026 season. However, the report also found that over 30 per cent of fans believe that investment is lacking across media, sponsorship and policy. 'The next step is to sustain that growth, right?' said Doherty. 'You see leagues historically in the U.S. and there's been some stop and start leagues, so we want to find ways to keep the growth, keep the momentum and help sustain them. 'I think forums like this and research like this ... helps back up this excitement with real data that supports a business case.' Since the PWHL was founded in 2023, there has been a 45 per cent increase in female hockey registrations in Canada, a historic record for the sport. Monica Wright Rogers, the new general manager of the WNBA's Toronto Tempo, was also a panellist at the espnW Conference. She said that she hopes the new women's basketball franchise will capture the imagination of young Canadian girls like the PWHL and NSL have. 'We want to inspire a generation to pick up a basketball and be a professional,' said Wright Rogers, who played collegiately and in the WNBA before moving into coaching and was the Phoenix Mercury's assistant GM before signing on in Toronto. 'If you're having fun at the sport, and you're young, and then you see women, professionally, living their lives, having fun and are good, that does something to a young person. 'I wouldn't be here if I didn't have the WNBA to aspire to, or the NWSL, or professional women putting their all on their playing field.' Hosted by ESPN's Sarah Spain, the third annual espnW Summit Canada had a dozen presentations. Some of the panels included Torque Strategies and IMI's presentation on the growth of women's sport, Wright Rogers' panel on women leading professional sports organizations, a discussion of how to build better facilities for women's sports, and an introduction of some of the founders getting support from Toronto Metropolitan University's Future of Sport Lab. 'This year, you'll see it's a lot more about grassroots and infrastructure and investment, really trying to expand the conversation and broaden that,' said Doherty during the lunch break. 'That's what we hope to continue with, year on year, when it comes to the research. 'Our agency is very, very passionate about women's sport, as is IMI, so we are going to continue to follow up on the report, new releases, new ideas, new insights that will come out on a biannual basis.'
CBC
2 days ago
- Business
- CBC
60% of Canadians say perception of women's sport has improved over 3 years: report
A new report says 60 per cent of Canadians believe perceptions of women's sport have improved over the past three years. The study also found 80 per cent of men consider themselves fans of women's sport. However, the report found that over 30 per cent of fans still say investment is lacking across media, sponsorship, and policy. Commissioned by Torque Strategies, in partnership with IMI, the report was presented at the espnW Conference at Toronto's Evergreen Brick Works on Wednesday morning. It also found 41 per cent of Canadians see women's sports as a national investment.
Winnipeg Free Press
2 days ago
- Business
- Winnipeg Free Press
Report: 60% of Canadians say perception of women's sport has improved over 3 years
TORONTO – A new report says 60 per cent of Canadians believe perceptions of women's sport have improved over the past three years. The study also found that 80 per cent of men consider themselves fans of women's sport. However, the report found that over 30 per cent of fans still say investment is lacking across media, sponsorship, and policy. Commissioned by Torque Strategies, in partnership with IMI, the report was presented at the espnW Conference at Toronto's Evergreen Brick Works on Wednesday morning. It also found that 41 per cent of Canadians see women's sports as a national investment. Thursdays Keep up to date on sports with Mike McIntyre's weekly newsletter. Since the Professional Women's Hockey League was founded in 2023 there has been a 45 per cent increase in female hockey registrations in Canada, a historic record for the sport. This report by The Canadian Press was first published June 18, 2025.
Malaysian Reserve
4 days ago
- Health
- Malaysian Reserve
C-Path's New Paper in Nature Reviews Drug Discovery Highlights How to Maximize the Regulatory Impact of Consortium-Based Projects
BRUSSELS and AMSTERDAM, June 16, 2025 /PRNewswire/ — The Innovative Health Initiative (IHI) and Critical Path Institute® (C-Path) today announced the publication of a peer-reviewed paper in Nature Reviews Drug Discovery, highlighting insights from multistakeholder global consortia launched over the past two decades to address barriers in drug development. Titled 'Delivering regulatory impact from consortium-based projects,' the paper presents a joint approach to addressing key challenges in developing tools to support regulatory decision-making. Drawing on the experience of cross-sector partnerships, the authors stress that collaboration alone is not enough to achieve meaningful impact on accelerating drug development. Key aspects to maximize regulatory impact include early regulatory engagement, clear evidentiary standards, and long-term planning for data access and sustainability. 'This work emphasizes the urgency—and feasibility—of building globally coordinated, cross-sector efforts to drive innovation for patients who have long been underserved,' said C-Path Vice President of Global Affairs Cécile Ollivier. 'By aligning stakeholders and lowering technical and regulatory barriers, we can reshape the drug development landscape.' As regulatory science becomes more central to translating innovation into patient benefit, the authors highlight the importance of taking a structured, strategic approach to regulatory issues, starting from the earliest stages of project planning and running right through to the post-project stage. 'We are collectively working to turn exciting advances in health research and innovation into real benefits for people and patients,' said Nathalie Seigneuret, Senior Scientific Project Manager at IHI. 'Regulatory science is key to making this happen, and we hope that this paper will help projects deliver results that meet regulators' needs.' Aligned with the IHI guide for applicants and project consortia on regulatory considerations for IMI and IHI projects, the paper outlines priorities for implementation: A clear regulatory strategy defined at project start A tailored data management plan aligned with regulatory goals A sustainability plan to ensure post-project data availability Early engagement with regulators led by experienced collaborators This paper reflects growing momentum for innovative and sustainable research whose results strive to accelerate medical product development and inform regulatory decision-making. Read the full paper, here, and supplementary material, here. About IHI The Innovative Health Initiative (IHI) aims to translate health research and innovation into real benefits for patients and society, and ensure that Europe remains at the cutting edge of interdisciplinary, sustainable, patient-centric health research. Health research and care increasingly involve diverse sectors. By supporting projects that bring these sectors together, IHI will pave the way for a more integrated approach to health care, covering prevention, diagnosis, treatment, and disease management. IHI is a partnership between the European Union and European industry associations representing the pharmaceutical, medical technology, biotechnology, digital health and vaccine industries, namely COCIR, EFPIA, EuropaBio, MedTech Europe and Vaccines Europe. IHI's total budget is EUR 2.4 billion. Half of this comes from Horizon Europe, the EU's research and innovation programme. The IHI industry partners have committed EUR 1 billion to IHI, and a further EUR 200 million can be committed by other organisations that decide to become Contributing Partners. IHI builds on the successes of the Innovative Medicines Initiative (IMI), and the IHI Programme Office continues to manage the IMI project portfolio. For more information visit and follow IHI on LinkedIn, Bluesky and Mastodon. About Critical Path Institute Founded in 2005, as a public-private partnership in response to the FDA's Critical Path Initiative, Critical Path Institute® (C-Path) celebrates its 20th anniversary as a vital, independent, nonprofit. C-Path's mission is to lead collaborations that advance better treatments for people worldwide. Globally recognized as a pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and initiatives that currently include more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations and pharmaceutical and biotech companies. With dedicated team members located throughout the world, C-Path's global headquarters is located in Tucson, Arizona and C-Path's Europe subsidiary is headquartered in Amsterdam, Netherlands. For more information, visit and follow C-Path on LinkedIn, X, Facebook, Instagram, BlueSky and YouTube. Media Contacts: Catherine BrettExternal Relations 2 541 8214 Roxan Triolo OlivasC-Path Communicationsrolivas@ 520-954-1634
Yahoo
4 days ago
- Business
- Yahoo
Teva 2024 Healthy Future Report: Advancing Innovation and Collaboration
NORTHAMPTON, MA / / June 16, 2025 / Improving access to medicines and healthcare requires a continued effort to develop new evidence-based solutions that address unmet needs. We engage in scientific collaborations with universities and research centers, start-ups, pharmaceutical companies, hospitals and health maintenance organizations to find external scientific solutions for internal R&D needs. These efforts increase our scientific visibility, while expanding and accelerating our innovative medicines portfolio, in line with the Step-up Innovation pillar of our Pivot to Growth business strategy. Ultimately, these innovation efforts can shorten discovery and development timelines and increase success rates in discovering new drug candidates, as well as finding solutions to advance our pipeline. Innovation and Collaboration Initiatives Our approach to innovation is multi-directional, connecting internal needs (identified through meetings and workshops), with external opportunities (identified through deep mapping, our database, AI-based scouting and other conventional approaches). Participation and membership of key industry and trade associations enriches Teva's network across the industry in line with our strategic focus areas and, as a partner of choice in the biotech ecosystem, we provide access to industry insights and our team's expertise. In the USA, we have partnerships with key universities to foster innovation, including Harvard, Thomas Jefferson, Pittsburgh, Oklahoma and Pennsylvania. In Europe, we have been part of the Innovative Medicines Initiative (IMI) since 2019. It is Europe's largest public-private partnership in life sciences and aims to develop next-generation vaccines, medicines and treatments. In 2024 we participated in more than eight IMI consortia - from drug discovery to development. Two new consortia focused on biologics and biomarkers: RealHOPE: aims to develop guidelines for improving handling of biologic drugs from the user end (pharmacies and patients/ caregivers). European Platform for Neurodegenerative Diseases (EPND): intends to establish a platform for storing and analyzing clinical and biological samples and data for biomarker discovery in progressive loss of structure or function of neurons (neurodegeneration). A strategic focus in our global innovation and collaboration activities revolves around growing and leveraging the health ecosystem in Israel, given Teva's deep ties to the country, and historic successes that include academic collaborations. Our engagement approach in Israel re-started in 2020, and since then we have established approximately 50 projects with Israeli researchers; these have received 18 partnership grants to date from the Israel Innovation Authority, two of which were given additional advanced grant funding in 2024. Key initiatives in our Israel-focused collaboration include: AION Labs: An alliance between Teva and three other global pharmaceutical companies, Amazon and the Israel Biotech Fund, AION creates and supports start-ups focusing on artificial intelligence (AI) in drug discovery and development. We play an active role in AION Labs, supporting with training and engagement. AION has created eight new start-up partnerships and plans to establish two more in 2025. In 2024 we partnered to establish CombinAble, an AION start-up, which focuses on antibody optimization. We also supported Celleryx, a start-up focused on AI early diagnostics of cancer and autoimmune diseases based on cell states. Organospheres: We work with multiple start-ups, pharma companies and academic groups through Organospheres, a consortium that is developing a human ex-vivo 3D system that could provide an alternative to animals being used in preclinical studies. BioInnovators Forum: Each year we offer 30 specialist PhD and post-doctorate students mentorship and training on translational research, and an annual innovation competition for students to develop solutions to unmet medical needs. Since 2020 the program has attracted over 150 graduates since inception, leveraging the skills of young scientists to drive future medical innovation. In 2024, entries included an at-home detection kit for tuberculosis based on breathing molecular analysis, and an IVF support device for the fertilization and implantation of embryos. This program has also been a source for identifying scientific talent to bolster our R&D function. Since 2020: 50 innovation projects with Israeli researchers 18 partnership grants received from Israel Innovation Authority 150 graduates taken part in BioInnovators Forum Public Health Research We collect and use public health and epidemiological data to estimate unmet economic, clinical and social needs of patients across our key TAs, including central nervous system, psychiatric, inflammatory and oncological conditions. Our research focuses on understanding the burden of illness, examining new clinical educational tools and evaluating ways to ensure patients have access to necessary treatments and enable HCPs, payers and other decision-makers to focus on areas with the greatest need. We can also identify appropriate patient populations and design clinical trials with relevant inclusion and exclusion criteria to benefit the maximum number of patients with unmet needs. In 2024, we presented our research at 176 congresses and published 55 peer-reviewed articles across scientific and medical journals. Teva Research and Development Academic Papers Published on PubMed in 2024 (55 total) 33% Research Innovation 29% Neurology/Psychiatry 5% Immunology 11% Migraine 4% Central Nervous System/Pain 7% Oncology 4% Cardiovascular 7% Respiratory To learn more, read the full 2024 Healthy Future the full 2024 Healthy Future Report Disclosures. View additional multimedia and more ESG storytelling from Teva Pharmaceutical on Contact Info:Spokesperson: Teva PharmaceuticalWebsite: info@ SOURCE: Teva Pharmaceutical View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
